PDVAC Executive summary 2020: Gonococcal Vaccine Preferred Product Characteristics

Overview

2020 WHO Product Development for Vaccines Advisory Committee (PDVAC) Virtual Consultation 7: Gonococcal Vaccine Preferred Product Characteristics : 4 December 2020

The intended outcomes of this PDVAC session were i) to obtain clear recommendations on the current draft GC vaccine PPC so that it can be finalised and published as normative guidance for GC vaccine development stakeholders, and ii) to identify the critical product attributes/characteristics that require further consideration for future policy and implementation discussions.